Our first generation of hydroxyethylamine transition-state mimetic BACE-1 inhibitors allowed us to validate BACE-1 as a key target for Alzheimer's disease by demonstrating amyloid lowering in an animal model, albeit at rather high doses. Finding a molecule from this series which was active at lower oral doses proved elusive and demonstrated the need to find a novel series of inhibitors with improved pharmacokinetics. This Letter describes the discovery of such inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2009.03.150 | DOI Listing |
Publication Analysis
Top Keywords
bace-1 inhibitors
8
second generation
4
generation bace-1
4
inhibitors
4
inhibitors optimisation
4
optimisation non-prime
4
non-prime side
4
side substituent
4
substituent generation
4
generation hydroxyethylamine
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!